SBI-3150

N/A

Report date: 2024/11/27 10:27:02

Base Information

Drug NameSBI-3150
Drug Alias NameSBI-3150AK-1910
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionDendritic cells inhibitorsB cells inhibitors5'-3' exonuclease PLD4 inhibitors
Targets5'-3' exonuclease PLD4
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesSbi Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSbi Biotech Co LtdAsahi Kasei Pharma Corp
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A